H.C. Wainwright Reiterates Buy Rating, $51 PT on Amarin (AMRN) Following FDA AdCom
Tweet Send to a Friend
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $51.00 price target on Amarin Corporation (NASDAQ: AMRN) after an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
